Clinical characteristics of Stenotrophomonas maltophilia bacteremia: A regional report and a review of a Japanese case series

Hirotaka Ebara, Hideharu Hagiya, Yuto Haruki, Eisei Kondo, Fumio Otsuka

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective Stenotrophomonas maltophilia is an emerging nosocomial pathogen that causes fatal infections in critically ill or immunocompromised patients. S. maltophilia bacteremia (SMB) is a rare condition, and its clinical characteristics in Japanese settings are not well known. Methods The medical charts of patients with SMB were retrospectively reviewed at two medical facilities (Okayama University Hospital and Tsuyama Chuo Hospital) for seven years. The data were analyzed along with those previously reported from other Japanese facilities. Result A total of 181 patients (110 men and 71 women) were evaluated. The major underlying diseases included hematologic malignancy (36.5%), solid organ malignancy (25.4%), and neutropenia (31.5%). The recent use of carbapenem was seen in 56.9% of the cases in total, and more than one-third of the patients in our hospitals were treated with carbapenem at the onset of SMB. of 28 (63.6%) of 44 cases treated for S. maltophilia, those who did not survive were more likely to have been treated with broad-spectrum antibiotics. A multivariate analysis revealed that a higher updated Charlson Comorbidity Index [odds ratio (95% confidence interval), 1.75 (1.11-2.75); p=0.015] and intubation [odds ratio (95% confidence interval), 12.6 (1.62-97.9); p=0.016] were associated with mortality in our cases. Pathogens were often resistant to ceftazidime but susceptible to minocycline, trimethoprim/sulfamethoxazole, and fluoroquinolones. The overall mortality rates within 30 and 90 days were 37.5% and 62.5%, respectively. Conclusion The clinical characteristics of SMB in Japanese cases were similar to those reported from other countries. Clinicians should be aware that breakthrough infection by S. maltophilia may occur during administration of carbapenem.

Original languageEnglish
Pages (from-to)137-142
Number of pages6
JournalInternal Medicine
Volume56
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

Stenotrophomonas maltophilia
Carbapenems
Odds Ratio
Confidence Intervals
Minocycline
Ceftazidime
Mortality
Fluoroquinolones
Sulfamethoxazole Drug Combination Trimethoprim
Immunocompromised Host
Hematologic Neoplasms
Infection
Neutropenia
Intubation
Critical Illness
Comorbidity
Multivariate Analysis
Anti-Bacterial Agents
Stenotrophomonas maltophilia bacteremia
Neoplasms

Keywords

  • Bacteremia
  • Breakthrough infection
  • Carbapenem
  • Nosocomial infection
  • Stenotrophomonas maltophilia

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Clinical characteristics of Stenotrophomonas maltophilia bacteremia : A regional report and a review of a Japanese case series. / Ebara, Hirotaka; Hagiya, Hideharu; Haruki, Yuto; Kondo, Eisei; Otsuka, Fumio.

In: Internal Medicine, Vol. 56, No. 2, 2017, p. 137-142.

Research output: Contribution to journalArticle

@article{8b59e48561714c479d7bbd5103551809,
title = "Clinical characteristics of Stenotrophomonas maltophilia bacteremia: A regional report and a review of a Japanese case series",
abstract = "Objective Stenotrophomonas maltophilia is an emerging nosocomial pathogen that causes fatal infections in critically ill or immunocompromised patients. S. maltophilia bacteremia (SMB) is a rare condition, and its clinical characteristics in Japanese settings are not well known. Methods The medical charts of patients with SMB were retrospectively reviewed at two medical facilities (Okayama University Hospital and Tsuyama Chuo Hospital) for seven years. The data were analyzed along with those previously reported from other Japanese facilities. Result A total of 181 patients (110 men and 71 women) were evaluated. The major underlying diseases included hematologic malignancy (36.5{\%}), solid organ malignancy (25.4{\%}), and neutropenia (31.5{\%}). The recent use of carbapenem was seen in 56.9{\%} of the cases in total, and more than one-third of the patients in our hospitals were treated with carbapenem at the onset of SMB. of 28 (63.6{\%}) of 44 cases treated for S. maltophilia, those who did not survive were more likely to have been treated with broad-spectrum antibiotics. A multivariate analysis revealed that a higher updated Charlson Comorbidity Index [odds ratio (95{\%} confidence interval), 1.75 (1.11-2.75); p=0.015] and intubation [odds ratio (95{\%} confidence interval), 12.6 (1.62-97.9); p=0.016] were associated with mortality in our cases. Pathogens were often resistant to ceftazidime but susceptible to minocycline, trimethoprim/sulfamethoxazole, and fluoroquinolones. The overall mortality rates within 30 and 90 days were 37.5{\%} and 62.5{\%}, respectively. Conclusion The clinical characteristics of SMB in Japanese cases were similar to those reported from other countries. Clinicians should be aware that breakthrough infection by S. maltophilia may occur during administration of carbapenem.",
keywords = "Bacteremia, Breakthrough infection, Carbapenem, Nosocomial infection, Stenotrophomonas maltophilia",
author = "Hirotaka Ebara and Hideharu Hagiya and Yuto Haruki and Eisei Kondo and Fumio Otsuka",
year = "2017",
doi = "10.2169/internalmedicine.56.6141",
language = "English",
volume = "56",
pages = "137--142",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "2",

}

TY - JOUR

T1 - Clinical characteristics of Stenotrophomonas maltophilia bacteremia

T2 - A regional report and a review of a Japanese case series

AU - Ebara, Hirotaka

AU - Hagiya, Hideharu

AU - Haruki, Yuto

AU - Kondo, Eisei

AU - Otsuka, Fumio

PY - 2017

Y1 - 2017

N2 - Objective Stenotrophomonas maltophilia is an emerging nosocomial pathogen that causes fatal infections in critically ill or immunocompromised patients. S. maltophilia bacteremia (SMB) is a rare condition, and its clinical characteristics in Japanese settings are not well known. Methods The medical charts of patients with SMB were retrospectively reviewed at two medical facilities (Okayama University Hospital and Tsuyama Chuo Hospital) for seven years. The data were analyzed along with those previously reported from other Japanese facilities. Result A total of 181 patients (110 men and 71 women) were evaluated. The major underlying diseases included hematologic malignancy (36.5%), solid organ malignancy (25.4%), and neutropenia (31.5%). The recent use of carbapenem was seen in 56.9% of the cases in total, and more than one-third of the patients in our hospitals were treated with carbapenem at the onset of SMB. of 28 (63.6%) of 44 cases treated for S. maltophilia, those who did not survive were more likely to have been treated with broad-spectrum antibiotics. A multivariate analysis revealed that a higher updated Charlson Comorbidity Index [odds ratio (95% confidence interval), 1.75 (1.11-2.75); p=0.015] and intubation [odds ratio (95% confidence interval), 12.6 (1.62-97.9); p=0.016] were associated with mortality in our cases. Pathogens were often resistant to ceftazidime but susceptible to minocycline, trimethoprim/sulfamethoxazole, and fluoroquinolones. The overall mortality rates within 30 and 90 days were 37.5% and 62.5%, respectively. Conclusion The clinical characteristics of SMB in Japanese cases were similar to those reported from other countries. Clinicians should be aware that breakthrough infection by S. maltophilia may occur during administration of carbapenem.

AB - Objective Stenotrophomonas maltophilia is an emerging nosocomial pathogen that causes fatal infections in critically ill or immunocompromised patients. S. maltophilia bacteremia (SMB) is a rare condition, and its clinical characteristics in Japanese settings are not well known. Methods The medical charts of patients with SMB were retrospectively reviewed at two medical facilities (Okayama University Hospital and Tsuyama Chuo Hospital) for seven years. The data were analyzed along with those previously reported from other Japanese facilities. Result A total of 181 patients (110 men and 71 women) were evaluated. The major underlying diseases included hematologic malignancy (36.5%), solid organ malignancy (25.4%), and neutropenia (31.5%). The recent use of carbapenem was seen in 56.9% of the cases in total, and more than one-third of the patients in our hospitals were treated with carbapenem at the onset of SMB. of 28 (63.6%) of 44 cases treated for S. maltophilia, those who did not survive were more likely to have been treated with broad-spectrum antibiotics. A multivariate analysis revealed that a higher updated Charlson Comorbidity Index [odds ratio (95% confidence interval), 1.75 (1.11-2.75); p=0.015] and intubation [odds ratio (95% confidence interval), 12.6 (1.62-97.9); p=0.016] were associated with mortality in our cases. Pathogens were often resistant to ceftazidime but susceptible to minocycline, trimethoprim/sulfamethoxazole, and fluoroquinolones. The overall mortality rates within 30 and 90 days were 37.5% and 62.5%, respectively. Conclusion The clinical characteristics of SMB in Japanese cases were similar to those reported from other countries. Clinicians should be aware that breakthrough infection by S. maltophilia may occur during administration of carbapenem.

KW - Bacteremia

KW - Breakthrough infection

KW - Carbapenem

KW - Nosocomial infection

KW - Stenotrophomonas maltophilia

UR - http://www.scopus.com/inward/record.url?scp=85010426645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010426645&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.56.6141

DO - 10.2169/internalmedicine.56.6141

M3 - Article

C2 - 28090041

AN - SCOPUS:85010426645

VL - 56

SP - 137

EP - 142

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 2

ER -